This article is more than 5 years old. Information may no longer be current.

VIDEO: Neurotech progresses in MacTel, glaucoma treatment pipeline

ByRichard Small

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO ― At the Ophthalmology Innovation Summit at AAO, Richard Small, CPA, CEO of Neurotech Pharmaceuticals, discusses the phase 3 progress of encapsulated cell therapy, or ECP, for the treatment of macular telangiectasia or MacTel, as well as their progress in treating glaucoma.